10-K: Brainstorm Cell Therapeutics Faces Financial Hurdles Despite NurOwn's Progress, Outlines Path Forward in Annual Report

Brainstorm Cell Therapeutics' 10-K filing reveals ongoing financial challenges and a strategic focus on advancing NurOwn for ALS through a planned Phase 3b trial, despite past regulatory setbacks.

Summary

• Brainstorm Cell Therapeutics' 10-K filing for the fiscal year ended December 31, 2024, highlights the company's commitment to developing and commercializing autologous cellular therapies for neurodegenerative diseases.
• The company's primary focus remains on NurOwn, a cell therapy platform for treating ALS, PMS, and AD.
• Despite completing Phase 3 ALS and Phase 2 PMS clinical trials, NurOwn has faced regulatory hurdles, including a refusal to file (RTF) letter from the FDA and an unfavorable vote from the Advisory Committee.
• Brainstorm is actively exploring the next steps for NurOwn, including a planned Phase 3b registrational trial for ALS, for which they have secured a Special Protocol Assessment (SPA) agreement with the FDA.
• The company is also expanding its exosome-based platform technology to explore new therapeutic applications.
• Brainstorm reported a net loss of $11.623 million for the year ended December 31, 2024, compared to a net loss of $17.192 million for the previous year.
• The company's ability to continue as a going concern is dependent on raising additional capital and achieving regulatory approval for NurOwn.
• Brainstorm currently employs 27 full-time employees and maintains facilities in the United States and Israel.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in clinical trial design and FDA alignment, the company faces financial challenges and regulatory hurdles. The future is uncertain and dependent on successful fundraising and regulatory outcomes.

Positives

• FDA granted a Special Protocol Assessment (SPA) agreement for the design of the Phase 3b trial of NurOwn in ALS.
• Alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn.
• Peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve suggests NurOwn may impact key biomarkers in ALS.
• The company is expanding its exosome-based platform technology to explore new therapeutic applications.
• The company regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

Negatives

• The company received a refusal to file (RTF) letter from the FDA regarding its BLA for NurOwn for the treatment of ALS.
• The Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.
• The BLA for NurOwn was withdrawn on November 3, 2023.
• The company has a history of losses and expects to incur losses for the foreseeable future.
• The company's ability to continue as a going concern is dependent on raising additional capital and achieving regulatory approval for NurOwn.

Risks

• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• The company is subject to securities class action litigation and other types of stockholder litigation.
• The company needs to raise additional capital to pursue its business objectives.
• Product development programs are based on novel technologies and are inherently risky.
• NurOwn may not demonstrate sufficient safety and efficacy to obtain regulatory approval.
• The company faces substantial competition in developing cell therapies for ALS and other neurodegenerative diseases.
• Political, economic, and military instability in Israel may impede the company's ability to execute its plan of operations.

Future Outlook

Brainstorm is focused on initiating and completing a Phase 3b trial and commercialization of NurOwn for ALS, if approved. The company is also strategically expanding its Exosome-based platform technology to explore new therapeutic applications.

Management Comments

• Brainstorm remains committed to the ALS Community and is actively exploring the next steps in support of NurOwn, including publication of emerging clinical data and development of a protocol for an additional clinical study.

Industry Context

The document provides context on the competitive landscape for ALS treatments, noting the presence of approved therapies and other experimental treatments under evaluation. It also discusses the increasing focus on research for ALS and other neurodegenerative diseases, as well as increased funding sources to expedite therapy development.

Comparison to Industry Standards

• The document mentions approved treatments for ALS, including Riluzole, Radicava, Relyvrio, and Qalsody, and notes that these therapies primarily focus on managing symptoms rather than disease modification.
• The document also mentions Corestem's NEURONATA-R inj., an autologous bone marrow mesenchymal stem cell (BM-MSC) therapy for ALS, which is commercialized in South Korea.
• The document notes that the Healy platform trial includes seven ALS investigational therapies to date: Zilucoplan; Pridopidine; Trehalose; Verdiperstat; CNM-Au8; ABBV-CLS-7262: DNL343.

Management Changes

Legal Proceedings

• The company is subject to a securities class action lawsuit and derivative actions related to NurOwn for the treatment of ALS, the Companys submissions to and communications with the FDA in support of the approval of NurOwn for the treatment of ALS, and the prospects of future approval of NurOwn by the FDA.
• 3D Communications, LLC filed a lawsuit against the Company in the U.S. District Court for the District of Delaware, captioned 3D Communications, LLC v. Brainstorm Cell Therapeutics, Inc., Case No. 1:24-cv-01286. The Complaint in this lawsuit brings a claim for breach of contract, and alleges that 3D Communications, LLC provided certain consulting and other services to the Company relating to a master services agreement and statement of work, and the Company has not timely paid the corresponding invoices.

Related Party Transactions

• The company has a commercial relationship with Ramot, the technology transfer group within Tel Aviv University, under a Research and License Agreement.
• The company is party to a July 2, 2007 subscription agreement and related registration rights agreement and warrants, amended July 31, 2009, May 10, 2012, May 19, 2014 and November 2, 2017 (together as amended, the ACCBT Documents) with ACCBT, a company under the control of Mr. Chaim Lebovits, our President and Chief Executive Officer.

Stakeholder Impact

• The company's ability to continue as a going concern is dependent on raising additional capital and achieving regulatory approval for NurOwn, which could impact shareholders, employees, and other stakeholders.
• The success of NurOwn as a treatment option for ALS, PMS, AD or other neurodegenerative diseases will depend on several factors, including educating treating physicians on how to use our NurOwn stem cell therapy, which could impact patients and the medical community.

Next Steps

• Initiating and completing a Phase 3b trial for NurOwn in ALS.
• Pursuing regulatory approval for NurOwn in ALS.
• Advancing clinical development of NurOwn in Progressive Multiple Sclerosis (PMS).
• Evaluating potential applications in other CNS disorders, including AD and Huntingtons Disease.
• Expanding the Exosome-based platform technology to explore new therapeutic applications.

Key Dates

Keywords

NurOwn, ALS, Brainstorm Cell Therapeutics, Phase 3b trial, SPA, FDA, Exosomes, PMS, AD, Clinical trial, Regulatory approval, Biotechnology